WhatFinger

WATCH: Alzheimer's Therapy Drug: Should We Pay $56,000 to Slow the Loss of Mom's Mind?

By Bill Whittle ——--June 25, 2021

Videos | CFP Comments | Reader Friendly | Subscribe | Email Us

Aduhelm sparks controversy as a therapy drug for Alzheimer's patients that attacks amyloid plaques in the brain, and slows the decline of memory and problem-solving by about 25% over time. It's not a cure, and it can't even restore lost mental capabilities. Now that the FDA has fast-tracked approval, should American taxpayers cover the $56,000/year per patient cost for relative minor results? Scott Ott, Stephen Green and Bill Whittle create 240 new episodes of Right Angle annually, thanks to our Members. Join us now at BillWhittle


Support Canada Free Press

Donate
Subscribe

View Comments
Bill Whittle——

Bill Whittle’s core message of common sense and decency has earned him a devoted following among those who value reasoned thought, civil dialogue and vigorous laughter. His powers of vivid storytelling, relentless logic, and self-deprecating humor join forces to apply time-tested principles to breaking news in memorable ways.

In addition to his compelling Firewall video essays, Bill Whittle joins Scott Ott and Stephen Green to create some four dozen new videos every month, thanks to the Members who fund this enterprise, and who enjoy a conservative enclave at his Members-only site.
Join the team who produces these videos, and find your people at BillWhittle.com

Listen to audio versions of Bill Whittle Now and Right

VIEW Comments

Sponsored
!-- END RC STICKY -->